4A
4AB.XETRA AbbVie Inc
- Market cap
- EUR 447B
- P/E
- 50.5x
- P/B
- 50.15x
- ROE
- -
- Dividend yield
- 2.37%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 4AB.XETRA undervalued?
Graham numberThe Graham number of AbbVie Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AbbVie Inc fundamental analysis
No fundamental analysis for AbbVie Inc yet.
AbbVie Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung canc…
Full company profileAbbVie Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AbbVie Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 25.6B | 28.2B | 32.8B | 33.3B | 45.8B | 56.2B | 58.1B | 54.3B | 56.3B | 61.2B | 66.3B |
| Gross Profit | 19.8B | 21.2B | 25.0B | 25.8B | 30.4B | 38.8B | 40.6B | 37.6B | 39.4B | 43.0B | 53.7B |
| Operating Income | 9.38B | 9.59B | 6.38B | 13.0B | 476M | 7.87B | 11.2B | 12.8B | 9.14B | 15.1B | 23.1B |
| EBITDA | 10.8B | 11.8B | 13.7B | 12.2B | 12.3B | 23.9B | 24.2B | 17.2B | 14.9B | 17.6B | 29.6B |
| Net Income | 5.95B | 5.31B | 5.69B | 7.88B | 4.62B | 11.5B | 11.8B | 4.86B | 4.28B | 4.23B | 11.5B |
| EPS | 3.65 | 3.31 | 3.68 | 5.31 | 2.62 | 6.50 | 6.66 | 2.74 | 2.41 | 2.38 | 6.50 |
| Balance Sheet | |||||||||||
| Total Assets | 66.1B | 70.8B | 59.4B | 89.1B | 151B | 147B | 139B | 135B | 135B | 134B | 148B |
| Total Liabilities | 61.5B | 65.7B | 67.8B | 97.3B | 137B | 131B | 122B | 124B | 132B | 137B | 152B |
| Shareholders' Equity | 4.64B | 5.10B | -8.45B | -8.17B | 13.1B | 15.4B | 17.3B | 10.4B | 3.33B | -3.27B | -4.58B |
| Cash & Short-term Investments | 6.42B | 9.79B | 8.06B | 39.9B | 8.48B | 9.83B | 9.23B | 12.8B | 5.56B | 5.26B | 10.8B |
| Total Debt | 36.8B | 37.4B | 40.3B | 66.7B | 86.1B | 76.7B | 63.3B | 59.4B | 67.1B | 69.1B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.04B | 9.96B | 13.4B | 13.3B | 17.6B | 22.8B | 24.9B | 22.8B | 18.8B | 19.0B | 19.8B |
| Capital Expenditure | 479M | 529M | 638M | 552M | 798M | 787M | 695M | 777M | 974M | 1.21B | 1.18B |
| Free Cash Flow | 6.56B | 9.43B | 12.8B | 12.8B | 16.8B | 22.0B | 24.2B | 22.1B | 17.8B | 17.8B | 18.6B |
| Ratios | |||||||||||
| ROE | 128.4% | 104.2% | - | - | 35.3% | 74.9% | 68.6% | 46.9% | 128.7% | - | - |
| ROA | 9.0% | 7.5% | 9.6% | 8.8% | 3.1% | 7.9% | 8.5% | 3.6% | 3.2% | 3.2% | 7.8% |
| Net Profit Margin | 23.2% | 18.8% | 17.4% | 23.7% | 10.1% | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% | 17.4% |
| Debt to Equity | 7.95x | 7.33x | - | - | 6.58x | 4.98x | 3.67x | 5.73x | 20.19x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AbbVie Inc dividends
- Dividend yield
- 2.37%
- Forward dividend
- 5.99 EUR
- Payout ratio
- 275.8%
- Ex-dividend date
- Jan 15, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 11.7B | 6.58 | 275.8% |
| 2024 | USD 11.0B | 6.22 | 257.7% |
| 2023 | EUR 10.5B | 5.94 | 216.7% |
| 2022 | USD 10.0B | 5.65 | 84.9% |
| 2021 | EUR 9.26B | 5.21 | 80.2% |
| 2020 | EUR 7.72B | 4.37 | 167.2% |
| 2019 | EUR 6.37B | 4.29 | 80.8% |
| 2018 | EUR 5.58B | 3.61 | 98.1% |
| 2017 | EUR 4.11B | 2.56 | 77.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns AbbVie Inc
- Insiders 0.11%
- Institutions 77.28%
- Public & others 22.61%
- Shares outstanding 1.77B
- Free float 1.76B
AbbVie Inc company profile
- Company name
- AbbVie Inc
- Ticker
- 4AB.XETRA
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 57,000
- Fiscal year end
- December
- Address
- 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400
- Phone
- 847 932 7900
- Website
- abbvie.com
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc management
10- Mr. Robert A. Michael CPACEO & Chairman of the Board · born 1970
- Mr. Scott T. ReentsExecutive VP & CFO · born 1967
- Dr. Azita Saleki Ph.D.Executive VP & COO · born 1963
- Dr. Roopal B. Thakkar M.D.Executive VP of Research & Development and Chief Scientific Officer · born 1972
- Mr. Jeffrey Ryan StewartExecutive VP & Chief Commercial Officer · born 1969
- Ms. Linda RaySenior VP & Chief Information Officer
- Ms. Elizabeth SheaSenior Vice President of Investor Relations
- Mr. Perry C. SiatisExecutive VP, General Counsel & Secretary · born 1975
- Mr. Demetris D. CrumExecutive VP & Chief Human Resources Officer · born 1981
- Mr. Wulff-Erik von BorckeSenior VP & President of Oncology